Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Tianlong Announces Global Release of GeneFlex Nucleic Acid Extractor and Gentier mini+ Real-time PCR System 2023-03-31 20:04
Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq 2023-03-31 20:01
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China 2023-03-31 10:00
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 2023-03-31 07:30
NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity 2023-03-31 03:03
Viva Biotech Announced 2022 Annual Results: 2023-03-31 00:25
DISCOVERY LIFE SCIENCES INSTALLS WORLD'S LARGEST COMMERCIAL FLEET OF NOVASEQ X PLUS SYSTEMS TO ACCELERATE GENOMIC RESEARCH WITH UNPRECEDENTED SPEED AND COST EFFICIENCY 2023-03-30 21:05
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization 2023-03-30 20:51
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC 2023-03-30 20:00
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200 2023-03-30 17:39
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023 2023-03-30 12:00
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients 2023-03-30 08:00
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063 2023-03-30 03:32
Broncus Medical (02216.HK) Announces Annual Results for 2022 2023-03-30 01:05
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy 2023-03-29 22:53
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer 2023-03-29 14:00
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
Innovent Announces 2022 Annual Results and Business Updates 2023-03-29 08:00
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation 2023-03-28 21:40
BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO 2023-03-28 21:20
1 40 41 42 43 44 212